|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome显示文摘AIM: To investigate the effect of rosuvastatin monotherapy on non-alcoholic steatohepatitis(NASH). At present there is no effective treatment for non-alcoholic fatty liver disease or its advanced form NASH.METHODS: This prospective study included 20 biopsy proven patients with NASH, metabolic syndrome(Met S) and dyslipidaemia. Biochemical parameters of the blood of the patients and an ultrasonography of the liver were performed at baseline. Then patients receivedlifestyle advice and were treated for a 12 mo period with rosuvastatin(10 mg/d) monotherapy. Patients were re-evaluated during the study at 3 mo intervals, during which biochemical parameters of the blood were measured including liver enzymes. A repeat biopsy and ultrasonography of the liver were performed at the end of the study in all 20 patients. Changes in liver enzymes, fasting plasma glucose, serum creatinine, serum uric acid(SUA), high sensitivity C reactive protein(hs CRP) and lipid profile were assessed every 3 mo. The primary endpoint was the resolution of NASH and the secondary endpoints were the changes in liver enzyme and lipid values.RESULTS: The repeat liver biopsy and ultrasonography showed complete resolution of NASH in 19 patients, while the 20 th, which had no improvement but no deterioration either, developed arterial hypertension and substantial rise in triglyceride levels during the study, probably due to changes in lifestyle including alcohol abuse. Serum alanine transaminase, aspartate transaminase, and γ-glutamyl transpeptidase were normalised by the 3rd treatment month(ANOVA P < 0.001), while alkaline phosphatase activities by the 6th treatment month(ANOVA, P = 0.01). Fasting plasma glucose and glycated haemoglobin were significantly reduced(P < 0.001). Lipid values were normalised by the 3rd treatment month. No patient had Met S by the 9th treatment month. Body mass index and waist circumference remained unchanged during the study. Thus, changes in liver pathology and function should be attributed solely to rosuvastatin treatment. A limitation of the study is the absence of a control group.CONCLUSION: These findings suggest that rosuvastatin monotherapy could ameliorate biopsy proven NASH and resolve Met S within 12 mo. These effects and the reduction of fasting plasma glucose and SUA levels may reduce the risk of vascular and liver morbidity and mortality in NASH patients. These findings need confirmation in larger studies. | Konstantinos Kargiotis Vasilios G Athyros Olga Giouleme Niki Katsiki Evangelia Katsiki Panagiotis Anagnostis Chrysoula Boutari Michael Doumas Asterios Karagiannis Dimitri P Mikhailidis | 2015 | World Journal of Gastroenterology2015，21，25： | 18 |
| 2 | Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options显示文摘 | Konstantinos Tziomalos Vassilios G. Athyros Asterios Karagiannis | 2012 | Current Vascular Pharmacology2012，，2： | 2 |
| 3 | The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification显示文摘 | Konstantinos Tziomalos Vasilios G Athyros Asterios Karagiannis Dimitri P Mikhailidis | 2010 | Current Opinion in Cardiology2010，，4： | 2 |
| 4 | Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis显示文摘 | Vasilios G Athyros Konstantinos Tziomalos Thomas D Gossios Theodora Griva Panagiotis Anagnostis Konstantinos Kargiotis Efstathios D Pagourelias Eleni Theocharidou Asterios Karagiannis Dimitri P Mikhailidis | 2010 | The Lancet2010，，9756： | 2 |
| 5 | Long-term Follow-up of Patients With Acute Hypertriglyceridemia-Induced Pancreatitis显示文摘 | Vassilios G. Athyros Olga I. Giouleme Nikolaos L. Nikolaidis Themistoklis V. Vasiliadis Vassilios I. Bouloukos Athanasios G. Kontopoulos Nikolaos P. Eugenidis | 2002 | Journal of Clinical Gastroenterology2002，，4： | 2 |
| 6 | Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease:an update显示文摘 | Vasilios G Athyros Konstantinos Tziomalos Niki Katsiki Michael Doumas Asterios Karagiannis Dimitri P Mikhailidis | 2015 | World Journal of Gastroenterology2015，，22： | 2 |
| 7 | Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management 显示文摘 | K Athyros VG Karagiannis A | 2010 | Nutr Metab Cardiovasc Dis2010，20，2： | 1 |
| 8 | Statins and renal function in patients with diabetes mellitus显示文摘 | Athyros VG Papageorgiou AA | 2003 | Curr Med Res Opin2003，19，7： | 1 |
| 9 | Safety and efficacy o显示文摘 | Athyros V G Tziomalos K Gossios T D | 2010 | Lancet2010，376，9756： | 1 |
| 10 | The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease: a subgroup analysis of the Greek atorvastatin mad coronary heart disease evaluation (GRACE) study 显示文摘 | Athyros VG Mikhailidis DP Papageorgiou AA | 2004 | J Clin Patho12004，57，7： | 1 |
| 11 | Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis显示文摘 | ATHYROS V G GIOULEME O I NIKOLAIDIS N L | 2002 | J Clin Gastroenterol2002，34，4： | 1 |
| 12 | Statins and renal function in patients with diabetes mellitus显示文摘 | Athyros V G Papageorgiou A A Elisaf M | 2003 | Curr Med Res Opin2003，19，7： | 1 |
| 13 | Clinical review:thepathogenetic role of cortisol in the metabolic syndrome:a hypothesis显示文摘 | Anagnostis P Athyros VG Tziomalos K | 2009 | J Clin Endocrinol Metab2009，94，8： | 1 |
| 14 | Endothelial function,arterial stiffness and lipid lowering drugs显示文摘 | Athyros VG Karagiannis A | 2007 | Expert Opin Ther Targets2007，11，9： | 1 |
| 15 | Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease 显示文摘 | Pehlivanidis AN Athyros VG Demitriadis DS | 2001 | Atherosclerosis2001，157，2： | 1 |
| 16 | The role of statins for the prima- ry and secondary prevention of coronary heart disease in women 显示文摘 | Tziomalos K Kakafika AI Athyros VG | 2009 | Curt Pharm Des2009，15，： | 1 |
| 17 | Effect of multifaetorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study显示文摘 | Athyros VG Mikhailidis DP Didangelos TP | 2006 | Curr Meal Res Opin2006，22，5： | 1 |
| 18 | The impact of serum uric acid on cardiovascular outcomes in the LIFE study显示文摘 | Daskalopoulou SS Athyros VG Elisaf M | 2004 | Kidney Int2004，66，： | 1 |
| 19 | Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study : a post-hoc analysis 显示文摘 | Athyros VG Tziomalos K Gossios TD | 2010 | Lancet2010，376，9756： | 1 |
| 20 | Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study显示文摘 | Athyros VG Elisaf M Papageorgiou AA | 2004 | Am J Kidney Dis2004，43，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员